Karolinska Development divests its holding in Inhalation Sciences
(Thomson Reuters ONE) -
STOCKHOLM - February 13, 2017. Karolinska Development AB (Nasdaq Stockholm:
KDEV) today announces the divestment by KDev Investments of its entire
shareholding in Inhalation Sciences AB, a company that markets PreciseInhale for
inhalation research, to a consortium compromising Inhalation Sciences' founder
Per Gerde, CEO Fredrik Sjövall and Råsunda Förvaltning AB.
KDev Investments, an investment fund jointly owned by Karolinska Development and
Rosetta Capital, retains an economic interest in Inhalation Sciences through an
earn-out agreement. Råsunda Förvaltning AB is a family owned holding company
providing expansion capital to innovative growth companies with international
potential.
Jim Van heusden, CEO of Karolinska Development, says: "We are continuously
evaluating options for our portfolio companies to retain and realize as much
value as possible. We are pleased Inhalation Sciences has been successful in
attracting Råsunda Förvaltning AB as anew investor, which will support the
Company towards future milestones. KDev Investments retains an economic interest
through an earn-out agreement, which has the potential to generate future
value."
No further financial details on this transaction will be disclosed.
For further information, please contact:
Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail: jim.van.heusden(at)karolinskadevelopment.com
David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson
Phone: +44 20 7638 9571; e-mail: KDev(at)citigatedr.co.uk
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB is an investment company focused on identifying
medical innovation and investing in the creation and growth of companies
developing these assets into differentiated products that will make a difference
to patients' lives and provide an attractive return on investment.
Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research institutes in
the Nordic region. The Company aims to build companies around scientists who are
leaders in their fields, supported by experienced management teams and advisers,
and co-funded by specialist international investors, to provide the greatest
chance of success.
Karolinska Development has established a portfolio of nine companies targeting
opportunities in innovative treatment for life-threatening or serious
debilitating diseases.
The Company is led by a team including investment professionals with strong
venture capital backgrounds, experienced company builders and entrepreneurs,
with access to a strong global network. For more information, please visit
www.karolinskadevelopment.com
Karolinska Development divests its holding in Inhalation Sciences:
http://hugin.info/143071/R/2077937/781812.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 13.02.2017 - 08:00 Uhr
Sprache: Deutsch
News-ID 523608
Anzahl Zeichen: 3579
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 174 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Karolinska Development divests its holding in Inhalation Sciences"
steht unter der journalistisch-redaktionellen Verantwortung von
Karolinska Development AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
